Nuvelo (Nasdaq: NUVO) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nuvelo (Nasdaq: NUVO)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (193)	10/4/2000 5:41:30 PM
From: keokalani'nui	Read Replies (1) of 286

Well will you look at this. Click Here! Related Quotes AMGN HYSQ 64 7/16 32 9/16 -2 5/16 +0 delayed 20 mins - disclaimer Wednesday October 4, 4:27 pm Eastern Time Hyseq to seek FDA permission to test first two drugs NEW YORK, Oct 4 (Reuters) - Hyseq Inc.'s Chief Executive said on Wednesday his genomics company plans to ask U.S. regulators by late 2001 for permission to begin human tests of two of its first two experimental medicines, one to prevent blood clots and the other to treat inflammatory diseases. Chief Executive George Rathmann said that he will ask the U.S. Food and Drug Administration for the green light to test one of two candidates it has identified that prevent platelets from clumping together to form blood clots. He said the sister proteins have the working names of IL-1Hy1 and IL-1Hy2. Rathmann, a founder of Amgen Inc. (NasdaqNM:AMGN - news), said that Hyseq (NasdaqNM:HYSQ - news) will decide by next year which of the two anti- inflammatory molecules will enter trials and added that the likely disease target will be either rheumatoid arthritis or inflammatory bowel disease. The other drug, which Rathmann said he plans to steer into human clinical trials, is CD39L4, a naturally occurring human protein that Hyseq discovered through its genomics technology which it said prevents formation of blood clots. Rathmann, interviewed at the UBS Warburg global sciences conference being held here, said the drugs have the potential of being safer than existing blood clot drugs and anti-inflammatory drugs. [Anyone have any idea what the RA target is?--Wilder]

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next